AL amyloidosis with IgD-lambda monoclonal gammopathy and lambda-type Bence-Jones protein: Successful treatment by autologous stem cell transplantation

Clinical and Experimental Nephrology

Volumn 14, Issue 5, 2010, Pages 506-510

  Sakurai Chin, Chanhyok ^a   Ubara, Yoshifumi ^a   Suwabe, Tatsuya ^a   Hoshino, Junichi ^a   Yonaha, Tomoki ^a   Hasegawa, Eiko ^a   Sumida, Keiichi ^a   Hiramatsu, Rikako ^a   Yamanouchi, Masayuki ^a   Hayami, Noriko ^a   Yamauchi, Junji ^a   Tominaga, Naoyuki ^a   Sawa, Naoki ^a   Takemoto, Fumi ^a   Masuoka, Kazuhiro ^a   Takaichi, Kenmei ^a   Oohashi, Kenichi ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

AL amyloidosis; High dose melphalan; IgD; MGUS; SCT; VAD

Indexed keywords

BENCE JONES PROTEIN; DAUNORUBICIN; DEXAMETHASONE; HEPARIN; IMMUNOGLOBULIN D; MELPHALAN; NORPHENAZONE; VINCRISTINE; WARFARIN;

ADULT; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN INFARCTION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; DYSARTHRIA; DYSPNEA; FEMALE; FLANK PAIN; HEART MUSCLE BIOPSY; HEMIPARESIS; HUMAN; HUMAN TISSUE; JAPANESE; JEJUNUM BIOPSY; KIDNEY BIOPSY; KIDNEY INFARCTION; MONOCLONAL IMMUNOGLOBULINEMIA; PROTEIN URINE LEVEL; PURPURA; SKIN BIOPSY;

AMYLOIDOSIS; BENCE JONES PROTEIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN D; MIDDLE AGED; PARAPROTEINEMIAS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 78149413432     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-010-0311-2     Document Type: Article

References (26)

1. RH Falk RL Comenzo M Skinner 1997 The systemic amyloidoses N Engl J Med 337 898 909 1:STN:280:DyaK2svjtlSjuw%3D%3D 10.1056/NEJM199709253371306 9302305 (Pubitemid 27408573)
2. RA Kyle ED Bayrd 1975 Amyloidosis: review of 236 cases Medicine (Baltimore) 54 271 299 1:STN:280:DyaE2M3hsFOrsQ%3D%3D
3. V Sanchorawala DG Wright DC Seldin LM Dember K Finn RH Falk, et al. 2001 An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis Bone Marrow Transpl 28 637 642 1:STN:280:DC%2BD3MnmsVagsQ%3D%3D 10.1038/sj.bmt.1703200 (Pubitemid 33014596)
4. M Skinner V Sanchorawala DC Seldin LM Dember RH Falk JL Berk, et al. 2004 High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study Ann Intern Med 140 85 93 1:CAS:528: DC%2BD2cXht1WgsL0%3D 14734330
5. JB Perz SO Schonland M Hundemer AV Kristen TJ Dengler M Zeier, et al. 2004 High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study Br J Haematol 127 543 551 1:CAS:528:DC%2BD2MXjslGjtA%3D%3D 10.1111/j.1365-2141.2004.05232.x 15566357 (Pubitemid 39627178)
6. T Gono M Matsuda N Dohi K Hoshi T Tada K Sakashita, et al. 2003 Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation Intern Med 42 72 77 10.2169/internalmedicine.42.72 12583623
7. T Gono M Matsuda Y Shimojima W Ishii J Koyama K Sakashita, et al. 2004 VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection Amyloid 11 245 256 10.1080/13506120412331336907 15678759 (Pubitemid 40115923)
8. O Yamazaki Y Ubara T Suwabe S Nakanishi J Hoshino N Sawa, et al. 2009 Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation Clin Exp Nephrol 13 522 525 1:CAS:528:DC%2BD1MXhsVertrbI 10.1007/s10157-009-0198-y 19499180
9. A Jaccard P Moreau V Leblond X Leleu L Benboubker O Hermine, et al. 2007 High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N Engl J Med 357 1083 1093 1:CAS:528:DC%2BD2sXhtVGqt7rF 10.1056/NEJMoa070484 17855669 (Pubitemid 47443213)
10. RA Kyle TM Therneau SV Rajkumar JR Offord DR Larson MF Plevak, et al. 2002 A long-term study of prognosis in monoclonal gammopathy of undetermined significance N Engl J Med 346 564 569 10.1056/NEJMoa01133202 11856795 (Pubitemid 34438817)
11. RA Kyle SV Rajkumar 2006 Monoclonal gammopathy of undetermined significance Br J Haematol 134 573 589 1:CAS:528:DC%2BD28XhtFSgsLbJ 10.1111/j.1365-2141.2006.06235.x 16938117 (Pubitemid 44255500)
12. H Wang C Gao L Xu Z Yang W Zhao X Kong 2008 Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China Cell Mol Immunol 5 293 298 1:CAS:528:DC%2BD1cXhtFylt7nL 10.1038/cmi.2008.36 18761817
13. ME González García C Fernández Alvarez V Robles Marinas AJ González Huerta MI Arias Miranda AP González Rodríguez, et al. 2008 A series of 618 cases of monoclonal gammopathies of undetermined significance: predictive factors of disappearance of monoclonal component or evolution to malignant gammopathies Rev Clin Esp 208 288 294 10.1157/13123188 18620653 (Pubitemid 351918739)
14. S Mseddi-Hdiji S Haddouk M Ben Ayed N Tahri M Elloumi S Baklouti, et al. 2005 Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases Pathol Biol (Paris) 53 19 25 1:STN:280:DC%2BD2M%2FktFCkuw%3D%3D
15. ML O'Connor DT Rice DH Buss HB Muss 1991 Immunoglobulin D benign monoclonal gammopathy. A case report Cancer 68 611 616 10.1002/1097- 0142(19910801)68:3<611::AID-CNCR2820680328>3.0.CO;2-5 1905973
16. J Bladé RA Kyle 1994 IgD monoclonal gammopathy with long-term follow-up Br J Haematol 88 395 396 10.1111/j.1365-2141.1994.tb05037.x 7803288
17. T Kinoshita H Nagai T Murate H Saito T Fukatsu T Hotta 1997 IgD monoclonal gammopathy of undetermined significance Int J Hematol 65 169 172 1:STN:280:DyaK2s3isFCksg%3D%3D 10.1016/S0925-5710(96)00557-9 9071822
18. P Rodon P Friocourt S Blanchet D Levallois 1996 Temporal artery involvement revealing AL amyloidosis and IgD monoclonal gammopathy J Rheumatol 23 189 190 1:STN:280:DyaK28vjsFKntQ%3D%3D 8838533
19. S Kimura R Iwatsuka T Aoki J Odawara N Asada M Yamakura, et al. 2007 Primary amyloidosis associated with IgD-lambda M-proteinemia Rinsho Ketsueki 48 1555 1558 18203516
20. YP Chong S Kim OB Ko JE Koo D Lee SH Park, et al. 2008 Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience J Korean Med Sci 23 819 824 1:CAS:528:DC%2BD1cXhsVKmsrnM 10.3346/jkms.2008.23.5.819 18955788
21. J Bladé JA Lust RA Kyle 1994 Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases J Clin Oncol 12 2398 2404 7964956
22. A Saux C Heroum C Sportouch F De Graeve A Lequellec M Pagès 2006 Amyloid cardiomyopathy: a rare cause of cerebral embolism Rev Neurol (Paris) 162 1128 1130 1:STN:280:DC%2BD28nlt1ertw%3D%3D
23. M Arias JA Abreu A Iglesias J Longo F Lecumberri F Vega 1996 Primary amyloidosis presenting as renal infarction Eur Radiol 6 346 348 1:STN:280:DyaK28zptFSgsw%3D%3D 10.1007/BF00180607 8798004
24. P Hausfater N Costedoat-Chalumeau Z Amoura P Cacoub T Papo G Grateau, et al. 2005 AL cardiac amyloidosis and arterial thromboembolic events Scand J Rheumatol 34 315 319 1:STN:280:DC%2BD2Mrit1Wlug%3D%3D 10.1080/03009740510015203 16195166 (Pubitemid 41215667)
25. B Adamu F Alshaebi M Ahmed B Beirouti 2008 Amyloidosis and vascular thrombosis Saud J Kidney Dis Transpl 19 137 141
26. AY Zubkov AA Rabinstein A Dispenzieri EF Wijdicks 2007 Primary systemic amyloidosis with ischemic stroke as a presenting complication Neurology 69 1136 1141 10.1212/01.wnl.0000276951.39112.2b 17846413 (Pubitemid 47517559)